Latham Advises on MapLight Therapeutics’ US$150 Million Private Placement Financing

MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, has announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately US$150 million, before deducting placement agent fees and estimated offering expenses. The financing is being led by new and existing institutional investors. The PIPE is expected to close on August 14, 2026, subject to customary closing conditions.

Latham & Watkins LLP represents the placement agents in connection with the PIPE with a corporate team led by partners Nathan Ajiashvili, Matt Bush, and Sandy Kugbei, with associates Jenny Li and Kan Ni.